New Pancreatic Cancer Drug Nearly Doubles Survival. Here’s What Patients Should Know

Daraxonrasib, a new pancreatic cancer drug, cut the risk of death by 60% in a Phase 3 trial. A doctor explains how it works, side effects and when it could reach patients.
By Published On: Aprile 14, 2026Categories: DesignCommenti disabilitati su New Pancreatic Cancer Drug Nearly Doubles Survival. Here’s What Patients Should Know

Share This Story, Choose Your Platform!

About the author : admin